Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $58.2 million.

  • Sutro Biopharma's Operating Expenses fell 2392.37% to $58.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $291.2 million, marking a year-over-year increase of 7.7%. This contributed to the annual value of $300.5 million for FY2024, which is 2365.63% up from last year.
  • Sutro Biopharma's Operating Expenses amounted to $58.2 million in Q3 2025, which was down 2392.37% from $67.1 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Operating Expenses registered a high of $85.9 million during Q1 2025, and its lowest value of $33.7 million during Q1 2021.
  • For the 5-year period, Sutro Biopharma's Operating Expenses averaged around $58.5 million, with its median value being $57.9 million (2022).
  • In the last 5 years, Sutro Biopharma's Operating Expenses soared by 5186.71% in 2021 and then crashed by 2392.37% in 2025.
  • Over the past 5 years, Sutro Biopharma's Operating Expenses (Quarter) stood at $45.7 million in 2021, then grew by 26.62% to $57.9 million in 2022, then increased by 21.98% to $70.6 million in 2023, then grew by 13.46% to $80.1 million in 2024, then dropped by 27.37% to $58.2 million in 2025.
  • Its Operating Expenses was $58.2 million in Q3 2025, compared to $67.1 million in Q2 2025 and $85.9 million in Q1 2025.